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Søren Brunak1Abstract
Risk assessment of toxicological compounds has traditionally
relied upon animal experimentation. Omics technologies, espe-
cially genomics and proteomics, generate large amounts of data
on genome-wide gene expression profiles, protein expression,
and protein interaction with xenobiotics (notably toxic ones),
enabling the study of chemical action across multiple scales of
complexity frommolecular to systems levels. This allows detailed
exploration of the mechanisms of toxicity. Although all omics
technologies may contribute to better understanding of the toxi-
cological impact of chemicals, their application in chemical risk
assessment has not yet been recommended for regulatory pur-
poses. With the recent development of the adverse outcome
pathway concept, the combination of the modular framework of
adverse outcome pathway, together with the network organisa-
tion within systems biology, offers an opportunity to shift the
paradigm of chemical risk assessment towards a better under-
standing of chemical toxicology mechanisms. In this review, we
discuss the advantages of the use of systems biology tools in
chemical riskassessment, aswell as thechallenges theypresent,
such as model over-parametrisation in quantitative modelling,
data gapmanagement in poorly studied substances and the lack
of expertise in bridging the new approaches to regulatory levels.
Addresses
1 Novo Nordisk Foundation Center for Protein Research, Faculty of
Health and Medical Sciences, University of Copenhagen, 2200
Copenhagen, Denmark
2 INSERM UMR-1133, CNRS UMR 8251, Unité de Biologie Fonc-
tionnelle & Adaptative (BFA), Paris Diderot Université, Sorbonne Paris
Cité, Paris 75013, France
Corresponding author: Brunak, Søren (soren.brunak@cpr.ku.dk)Current Opinion in Toxicology 2019, 15:48–54
This review comes from a themed issue on Risk Assessment in
Toxicology
Available online 12 March 2019
For a complete overview see the Issue and the Editorial
https://doi.org/10.1016/j.cotox.2019.03.003
2468-2020/© 2019 The Authors. Published by Elsevier B.V. This is an
open access ar ticle under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords
Systems biology, Chemical risk assessment, Systems toxicology,
Adverse outcome pathway, Integrated approaches to testing and
assessment, Read across.Current Opinion in Toxicology 2019, 15:48–54Introduction
Nowadays, one of the main goals for safety assessment is
to replace animal testing with more advanced technol-
ogies, which can explain and extrapolate methods both
in vitro or in silico [1]. Traditionally, in vivo measurements
of lower adverse effect levels and the no observed
adverse effect level are used in chemical risk assessment
[2]. Furthermore, physiologically based pharmacokinetic
(PBPK) modelling is used in risk assessments, where
these models serve as adjuncts to modes of action of
toxic chemicals. Human health risk assessments have
traditionally used doseeresponse relationships to
quantify and characterise the potential adverse health
effects in humans. Already in the early 70s, the avail-
ability of computers paved the way for the use of PBPK
models [3], which since then have been used and
approved by the authorities for chemical risk assess-
ment. This has been done through pharmacokinetics,
which studies the movement over time of a chemical
and its metabolites in biological fluids and tissues [4].
This type of modelling allows the calculation of tissue
exposure doses of chemicals and their metabolites over a
range of exposure conditions and species [5].
On the other hand, adverse outcome pathways (AOPs)
are a relatively recent development, used to describe
toxic events. AOPs, first described by Ankley et al., [6]
in 2010, were launched by the Organisation for Eco-
nomic Cooperation and Development (OECD) in
2012 as a pragmatic tool to describe linked causally
related events and their result as adverse outcomes.
AOPs are formed by a molecular initiating event (MIE)
and a series of key events (KEs), organised by
increasing complexity, towards an adverse effect [7,8].
Although this tool was developed to be a linear
sequence of events, a new approach attempts at
branching AOPs to develop AOP networks, which con-
siders the combination of multiple pathways, and link-
ing one MIE with several AOPs [9]. In addition,
quantitative AOPs (qAOPs) aim to combine the expo-
sure metrics and toxicokinetics from PBPK models such
that they supplement the tools used to support risk
assessment [10].
With the increased number of studies integrating the
AOP concept, some questions appeared. For example,www.sciencedirect.com
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rodents and humans and across other species represents
a significant difficulty. qAOP development can require a
significant resource investment, and except for rich
biological and toxicological knowledge bases on AOPs
such as the aromatase inhibition and other related
endocrine pathways, it might be not realistic to expect
much qAOP development in the near future [11].
Finally, interindividual and intraindividual variability in
exposures is growing in importance, but its introduction
into risk assessment is very challenging. Also, the ho-
mogeneity of the used rodent populations makes it
almost impossible to account for human variation
[12,13]. Different response thresholds in the different
models might also affect doseeresponse curves [14].
Mechanistic toxicology, the study of how chemicals cause
toxicity to living organisms, attempts to unravel the un-
derlying mechanisms and characterise their progression
towards adverse outcomes. The description of the rela-
tionship between exposure to a toxic substance and the
toxicological outcome has not been amajor priority in the
methods and models used in chemical risk assessment.
One of the main challenges in chemical risk assessment
remains the high number of chemicals with limited or no
toxicological information. Data used for mechanistic
understanding in chemical risk assessment rely on a
limited number of dose and time points, which makes it
difficult to model doseeresponse curves with low un-
certainty. A reductionist approach has governed the
chemical risk assessment principles in the past decades
[15]. Few specific endpoints were analysed to account for
toxicity, which made it more difficult to unravel the
complexity of the events underlying a toxic exposure.
Read-across (RAX) approaches, a hypothesis-driven
methodology based on data gap filling, has generally
been accepted by regulatory agencies, traditionally
using chemical similarity between the source and target
substance or quantitative structure activity relation-
ships. Such RAX approaches were accompanied by
uncertainty factors and weight-of-evidence scores
[6,16,17] and suggest an approximation of toxicological
events for new and existing toxic chemicals [18].
However, there is no standard method for measuring
biological similarity and it has been recently accepted
that RAX approach can be strengthened with additional
data from a multitude of different approaches, such as
in vitro screening, omics data, systems biology and their
integration through computational models [8]. The use
of high-throughput techniques is a step closer to a
holistic approach and wider understanding of the
mechanisms of toxicity. However, Hartung et al. [19]
already outlined the limitations of the approach,
pointing out the uncertainty associated with these
methods because cell-based assays may not exactly
predict relevant biological effects. Besides, single
in vitro assays are unlikely to yield a perfect result ofwww.sciencedirect.comthe toxic event, which highlights the need for inte-
grated testing strategies that can model the toxic event
elements to understand each step [20].
Systems biology, comprehensive approaches that help
understand the properties of complex, dynamic and
nonlinear multilevel biological systems, through the
subdomain systems toxicology has the potential to pro-
vide the quantitative mechanistic models to address
these issues. Systems toxicology can use different levels
of information from integrating diverse sources of data as
a means to provide deep mechanistic understanding of
the underlying toxicological effects, hence allowing for
adverse outcome prediction, providing a new paradigm
for chemical risk assessment [1].
The behaviour of each factor in a complicated problem
in isolation does not explain the overall behaviour of the
nonlinear interactions between the biological compo-
nents. Therefore, systems biology supplements the
reductionist approach, by integrating evidence instead
of separating the different biological levels d mole-
cules, cells, tissues, organs, individual and populationd
and aims to better understand the systemic, dynamic
state in living organisms [21,22]. It also allows us to
investigate the multifunctionality of genes and path-
ways and help to elucidate the effects of external ex-
posures such as diet, lifestyle and patient care [9].
Data integration and curation in systems
biology
The integration of different ‘omics’ measurements,
coming from diverse technologies (genomics, tran-
scriptomics, metabolomics, proteomics, epigenetics),
aids to assess chemical effect at the system biology level.
The advances in the different ‘omics’ technologies, as
well as the increase in large publicly available data sets,
coupled with the development of new modelling ap-
proaches have also increased our understanding of
toxicological events and effects at multiple biological
levels [23]. Among the databases, a short list is
presented in the following list:
- TOXsIgN: a cross-species repository for toxicoge-
nomics signatures describing more than 450 distinct
chemicals and their 8491 associated signatures [24].
- BD2K-LINCS: 350 data sets have been generated,
including transcriptomics, proteomics, epigenomics,
cell phenotype and competitive binding profiling
assays [25].
- Dixa: a data infrastructure for chemical safety assess-
ment. 95 toxicogenomics studies on 469 compounds
[26].
- TOXicology Data NETwork (TOXNET) is a website
hub connecting to several toxicology data files [27].
- ToxCast and Tox21contain data on more than 9000
chemicals for more than 1000 different endpoints
[28].Current Opinion in Toxicology 2019, 15:48–54
Figure 1
Reductionist approach to model key event relationships. An AOP is
formed by a molecular initiating event (MIE) which is triggered by an
exposure to a stressor, and it activates a subsequent sequence of key
events (KEs) to produce an adverse outcome (AO). By separating each
key event relationship, dose–response relationship (stressor-MIE) and
activity–response relationship (KE–KE and KE–AO) can be modelled
individually. Using this approach, we can understand the individual re-
lationships, which are then reconstructed to the holistic approach to un-
derstand the overall quantitative effect of the toxic event. AOP, adverse
outcome pathway.
50 Risk Assessment in Toxicology- ToxRefBD contains results for thousands of animal
toxicity tests [29].
- Chemical Effects in Biological Systems, a database
housing data of interest for health scientists, as it
displays data in the context of biology and study
design. It allows data integration across studies [30].
- ChemProt, a publicly available compilation of chemi-
caleproteinedisease annotation resources, of rele-
vance when studying the systems pharmacology of
small molecules across multiple layers of complexity,
from molecular to clinical levels [31].
- CTD, the comparative toxicogenomics database in-
cludes more than 30.5 million toxicogenomic connec-
tions relating chemicals/drugs, proteins/genes,
diseases, pathways, gene ontology annotations [32].
Systems biology and Integrated Approaches to
Testing and Assessment
Systems biology should contribute greatly to the Inte-
grated Approaches to Testing and Assessment (IATA)
proposed by the OECD [33]. IATA consists of struc-
tured approaches that integrate different types of data
and rank them to perform hazard identification, char-
acterisation of drug potency and safety assessment of
chemicals [34]. The initial step of IATA is to gather
relevant information existing at the specific compound
or endpoint levels, from which a first conclusion about
chemical risk can be derived. Omics data provide both
gene- and pathway-level read-outs (e.g. changes in in-
dividual gene expression levels or statistical indices for
the differential regulation of sets of genes within a
specific biological pathway) that can be used for
selecting measurable and relevant biomarkers. For
example, Suter et al. [35] have shown that combining
transcriptomics with proteomics and metabolomics data
improved the ability to provide more specific biomarker
candidates for liver hypertrophy, bile duct necrosis and/
or cholestasis and proximal tubule damage [35,36]. One
of the benefits of such an approach is the use of inter-
connected data from in silico experiments and experi-
mental data (in vitro, in vivo).
Although IATA provides structured data integration, it
does not necessarily offer any mechanistic rationale. On
the other hand, AOPs can provide the basis for mecha-
nistic theory (OECD, 2013). AOPs represent chemical
agnostic type of pathways, linking a linear sequence of
events, from the interaction of substances with initi-
ating molecular events to the generation of key events at
the cellular or systems level, which ultimately leads to
an observable adverse effect (adverse outcome) at the
individual or population level [33]. Thus, the AOP
framework describes the progression of a toxicity
pathway from the molecular origin to the population
outcome, through a series of measurable mechanistic
responses that could be integrated with IATA [33,37].
For a more comprehensive and biologically realistic
integration of the available knowledge in the form ofCurrent Opinion in Toxicology 2019, 15:48–54KEs and key event relationships, Wittwehr et al. [38]
described how the use of these aspects can be used as
a foundation for construction of AOP networks, trans-
forming the linear sequence of events in AOPs to a
network that better explains the biology behind the
toxic events.
Systems biology and AOP
Although the AOP and systems biology concepts are
different, their complementarity of them might further
shift the paradigm of chemical risk assessment towards a
better understanding of chemical toxicology mecha-
nisms. AOP describes a transition of system states,
integrating different scales of organisation in a linear
framework which, as explained previously, can be
transformed into a network interconnecting the
different modules that form the AOP. Systems biology,
having similar qualities as AOP, provides a network
organisation which considers the dynamic aspect inside
this organisation. Furthermore, mathematical models are
often implemented to link the experimental data to
biological outcomes in systems biology [39]. For
example, doseetime network identification, based on
ordinary differential equations, applied on toxicoge-
nomics data, has allowed for deriving mechanisms
explaining drug-induced liver injury and carcinogenicity
[11].
Contrary to systems biology, the AOP concept has been
recognised as a linear and simple model to provide the
basis for pragmatic decisions by the regulators. This,
together with the limited amount of data and expertise,
might explain why the translation of AOPs intowww.sciencedirect.com
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AOP networks, as explained previously, help bridge
linear AOPs and systems biology by incrementing the
complexity of AOPs and developing more biologically
relevant frames for them. Promising results start to be
reported such as the use of qAOPs that showed popu-
lation-level decrease in the fathead minnow or its use
with synthetic glucocorticoids in fish [40,41]. Some
mathematical models applied to AOPs appear feasible,
and they may be regarded as transition stages to systems
biology models and implemented in the online ency-
clopedia of AOPs (https://www.effectopedia.org/) [42].
The inclusion of hundreds of independent events is still
challenging from the mathematical model point of view,
especially because metabolites, genes and proteins play
roles in several different pathway at the same time.
Among the limitations of mathematical model of com-
plex mechanisms, one is the limited amount of availableFigure 2
Integration of systems biology into the AOP concept. Systems biology consis
different types of omics evidence; computational methods that help understan
molecules and the biological part, in this case chemical risk assessment, giving
outer circle of the figure, describe the different steps that help enrich the know
outcome pathway; KE, key event; MIE, molecular initiating event; WoE, weigh
www.sciencedirect.comdata that can lead to overfitted models with too many
parameters. Using KEs as individual AOP components,
it is possible to model the quantitative correlation for
each key event relationship (Figure 1).
Thus, genomic data help to identify plausible MIEs.
Lan et al. [43] used a toxicogenomics approach to obtain
quantitative information for genotoxicity assessment
based on DNA damage. Aguayo-Orozco et al. [44]
analysed a time-series gene expression data to explore
mechanisms of 28 chemical-induced hepatic steatosis
toxicities at 3 different concentrations. Proteineprotein
interaction analysis and other pathway analysis can
contribute in deciphering the evolution of the toxicity
across all levels of the organism: molecule, cell, tissue,
organ and individual (also known as KEs). Repeated
analysis at different dosage levels and times can explain
the doseeresponse and timeeresponse relationships.ts mainly of three parts, starting with the technology used to obtain the
ding the underlying structure and mechanisms within the cell and between
a biological outcome. All systems biology methodologies, depicted on the
ledge at the AOP level (inner circle). AO, adverse outcome; AOP, adverse
t-of-evidence.
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52 Risk Assessment in ToxicologyWith the increasing access to transcriptomic dosee
response data in toxicology and risk assessment,
genomic doseeresponse analysis can be performed to
support screening-level risk assessments for environ-
mental agents and software, for example, BMDExpress
can help for such analysis [43,45].
Although technological advances have facilitated the
production of data for mechanistically driven toxicology,
we are facing new challenges in how such data are
standardised, processed, modelled, interpreted and
quantified. Modelling and incorporation of further data,
such as disease data, mutation effect studies, patient
records and adverse event information, could help to
explain the toxic effects at the population level [46].
Ultimately, when a new compound, similar to a previous
one, is to be assessed, RAX methods could be exploited
to reduce analysis that is expensive and time-
consuming. The complementarity of systems biology
within the AOP concept is depicted in Figure 2.
There are high expectations of systems biology in
chemical risk assessment, although some issues are yet
to be tackled:
- Best practices for generating, collecting, storing,
curating and integrating ‘omics’ data are essential to
correctly interpret the data. In this context, a database
resource (AOP-DB) has been developed, aggregating
associations between genes and their related chem-
icals, diseases, pathways, species, ontologies and gene
interactions [47]. Levering the wealth of publicly
available data, covering chemical effects on biological
systems, can lead to computationally predicted AOPs
that might explain the mechanism behind a toxico-
logical event [48].
- Processing of ‘omics’ data may generate some un-
certainties in the interpretation of the outcomes, and
some weight-of-evidence approaches should be inte-
grated to make the results originating from these
various technologies more reliable. For example, with
gene expression data, depending on the technology,
the normalisation process, the specificity of the cell
types or tissues considered, the dose and time
point and the expression change of a gene might be
highly significant, resulting in false interpretations.
Therefore, the combination of outputs from different
technology platforms and data-processing algorithms
must be fitted and validated for each study
independently.
- The distinction between species needs to be specified
in the models. Although at the gene level, the trans-
lation from one species to humans is not always clear,
and chemical perturbations at the pathway level may
be more conserved, facilitating the use of data from
different species to extrapolate to humans. Therefore,
extrapolation across species can then be improved by
focussing on the similarity of biological pathwaysCurrent Opinion in Toxicology 2019, 15:48–54among species, as opposed to the traditional approach
of direct comparison of adverse events, or specific
molecules [49e51]. However, it has to be noted that
qualitatively similar (or identical) systems may have
different quantitative behaviours, and the kinetics are
not considered in such extrapolations.
Conclusion
The use of high-content omics data sets has led to
numerous publications on chemical MOAs [52e55].
However, it is still a scientific requirement to validate
these results with additional biochemical or physiolog-
ical studies. The AOP approach provides a platform that
aims to meet this scientific requirement while
supporting the use of omics data sets in risk assessment.
Systems biology through systems toxicology can be
applied to develop new models that can assess chemical
compounds by RAX, offering a new way of performing
chemical risk assessment with better accuracy and lower
cost and time consumption. To develop these models,
systems toxicology uses existing data on exposure ef-
fects of pharmaceutical, industrial and environmental
compounds, on different organisms, as well as the
existing pathways correlated to adverse outcomes. With
the advances in omics technologies and the generation
of big data, these models will likely be even more ac-
curate. In addition, the integration of systems biology
into AOPs could allow for maintaining the linearity of
the biological pathway in AOP and at the same time
include the network and dynamic features, contributing
to the translation from one observation to another (i.e.
from molecular event to cellular event to adverse
outcome). This linear depiction of AOPs is convenient
and useful, but it is an abstraction of the molecular level
biology. The mechanistic biology that underlies AOPs,
described in some detail in qAOPs, will extend its use by
including feedback and feed forward loops. This could
facilitate the transition from the use of omics technol-
ogies in research for regulatory purposes.
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